- Urva et al 81st Annual Scientific Sessions of the American Diabetes Association. Jun 2021
- Coskun T, Urva S, Roell WC, et al. LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept. Cell Metab. 2022;34(9):1234-1247.e9.
- EMA/CHMP review (EMA, 2017)
LY3437943 is generally well-tolerated in patients with T2D
Key messages
- A 12-week Phase 1 multiple-ascending dose study in patients with T2D was performed to assess the overall safety, tolerability PK, and PD profiles of LY3437943, a novel single peptide and triple agonist for GIP, GLP1, and glucagon receptors.
- LY3437943 is similar in overall safety vs the incretin class and is generally well-tolerated, apart from at higher doses when some GI intolerability transiently occurs.
- The PK profile studies attained a Tmax 12–48 hours post-dose, the half-life was ~6 days (therefore supporting once-weekly dosing), and the AUC(0-tau) and Cmax were proportional across the dose range studied.1
- There were further significant decreases in plasma glucose, HbA1c, and body weight.
